Image intended to aid understanding of the article / GPT CAR-T (chimeric antigen receptor T-cell) therapies, known as “dream cancer treatments,” are undergoing a major evolution that could extend their use beyond blood cancers to solid tumors and autoimmune diseases. According to
2026-05-29
Samch당 Pharmaceutical Samch당 Pharmaceutical is raising expectations for the commercialization of its oral insulin candidate, 'SCD0503,' after receiving approval for its European Phase 1 clinical trial plan. Samch당 Pharmaceutical said in a disclosure on the 29th that the European
2026-05-29
Image for illustrative purposes / GPT Chinese researchers have developed a new technology that can diagnose kidney fibrosis at an early stage using only a urine test and assess disease severity. According to Chinese biotechnology news outlet Bioon on the 29th, a research team led
2026-05-29
Image for illustrative purposes / GPT A series of studies investigating the complex biological causes of autism spectrum disorder (ASD) has raised expectations for the development of new diagnostic and treatment approaches. According to BioOn and other foreign media outlets on th
2026-05-29
Image for illustrative purposes / GPT Chinese researchers have identified, for the first time worldwide, the role of retinal organoids as a “bridge” connecting severed optic nerves. According to Chinese biotechnology news outlet BioOn on the 29th, a research team led by Professor
2026-05-29
Jethma Jethma’s botulinum toxin JTM201 has demonstrated noninferiority to the comparator Botox in a Chinese phase 3 trial, signaling progress toward entering the Chinese market. Jethma said in a disclosure on the 29th that it had obtained positive results from the first-stage pha
2026-05-29
Image for illustrative purposes / GPT AstraZeneca has released data showing that a drug candidate for a rare disease that failed in a Phase 3 trial improved survival by 62% in a specific patient group, and is making another attempt to secure regulatory approval. According to the
2026-05-29
Image for illustrative purposes / GPT China’s Dizal Pharma has challenged Johnson & Johnson (J&J) in the first-line treatment market for non-small cell lung cancer with EGFR exon 20 insertion mutations. According to U.S. biotech publication Fierce Pharma on the 29th local time, D
2026-05-29
Image for illustrative purposes / GPT Bristol Myers Squibb’s (BMS) next-generation targeted protein degrader reduced the risk of disease progression or death by more than half in patients with relapsed or refractory multiple myeloma. According to results presented May 29 at the a
2026-05-29
Hanmi Pharmaceutical Hanmi Pharmaceutical is accelerating commercialization after receiving approval for a domestic Phase 3 clinical trial of HCP1803-4, a treatment for essential hypertension. Hanmi Pharmaceutical announced on the 29th that it had received approval from the Minis
2026-05-29
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
